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Objectives: Several imaging modalities are commonly performed during work-up of intraductal papillary
mucinous neoplasm (IPMN), but guidelines do not suggest any one technique. The aim of this study was
to evaluate tumour and duct measurements by computed tomography (CT) and endoscopic ultrasound
(EUS) and their ability to predict high-grade dysplasia (HGD) and cancer within pancreatic IPMN.
Methods: Patients with IPMN who underwent preoperative CT and EUS between 2001 and 2009 were
selected. Data were gathered retrospectively from medical records.
Results: The study group was comprised of 52 patients, 33% (17/52) of whom had HGD or cancer. On
fine needle aspirate (FNA), neither carcinoembryonic antigen (CEA) >200 nor cytological analysis corre-
lated with malignancy. In multivariate analysis, duct size 1.0 cm (P = 0.034) was a significant predictor
of HGD or cancer, and diameter on CT scan (P = 0.056) approached significance. Lesion diameter of
 2.5 cm on CT scan identified malignancy in 71% (12/17) of patients (P = 0.037). When analysed, all
patients with HGD or cancer had a lesion diameter2.5 cm and/or a duct diameter1.0 cm by CT scan.
Conclusions: The use of radiographic criteria on CT including lesion size 2.5 cm and/or pancreatic
duct diameter 1.0 cm appears to reliably identify patients with either HGD or invasive cancer. High-
resolution CT scanning may obviate the need for EUS and FNA in patients with suspected IPMN.
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Introduction
Pancreatic resection remains a complex and potentially morbid
operation which is associated with overall rates of in-hospital
mortality and perioperative complications as high as 6.5% and
35.6%, respectively.1,2 Appropriate patient selection remains para-
mount in surgical decision making. Unlike other surgical diseases
of the pancreas, the definitive preoperative diagnosis of malignant
intraductal papillary mucinous neoplasm (IPMN) remains
elusive in diagnostic testing. While some patients continue to
undergo pancreatic resection for benign disease, an unknown
number remain under clinical observation and are harbouring
malignancy. Computed tomography (CT), used broadly as an
initial diagnostic imaging technique, was not useful for distin-
guishing benign frommalignant disease until the advent of multi-
detector scanning technology.3 Endoscopic ultrasound (EUS) has
substantially improved diagnostic accuracy and staging in a
number of gastrointestinal malignancies, including oesophageal
and rectal cancer.4–7 This modality has also been applied in IPMN
in efforts to improve the determination of benign vs. malignant
disease.8–13 However, a growing body of evidence suggests the
sensitivity and accuracy of EUS in the preoperative diagnosis of
malignant IPMN are low.3,14–16
The published international consensus guidelines for the man-
agement of IPMN17 suggest resection of IPMN if it is main duct
type or if it is branch duct type with a lesion size of 3.0 cm, or
if symptoms, mural nodules or positive cytology are present.
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However, these guidelines do not suggest any particular imaging
modality. A year after these guidelines were published, a study
from the Mayo Clinic demonstrated that no malignancies were
missed using these criteria, but only 15% of patients who under-
went resection had cancer.18 This suggests that there is room for
improvement in patient selection as many patients undergo resec-
tion for benign disease. The current study aims to examine the
accuracy of preoperative diagnostic techniques in patients with a
histopathological diagnosis of IPMN with high-grade dysplasia
(HGD) or invasive cancer, specifically focusing on the utility of
CT and EUS.
Materials and methods
The Oregon Health & Science University Institutional Review
Board approved this study. All patients with a surgical pathology
specimen demonstrating IPMN and dated between January 2001
and July 2009 were identified. Data were then gathered from their
electronic medical records in a retrospective fashion. Information
was collected on demographics, presentation, work-up, proce-
dures, pathology, hospital course and longterm follow-up. Sixty
patients were initially identified, but, for reasons including incom-
plete work-up and evaluation, eight were eliminated. The remain-
ing 52 patients were evaluated using spss pasw Version 18 (SPSS,
Inc., Chicago, IL, USA) statistical software for means and frequen-
cies. Contingency tables were constructed to look at the correla-
tion between individual tumour and patient characteristics
including HGD, invasive cancer, carcinoembryonic antigen (CEA)
value, gender, symptoms, size of tumour on both CT and EUS,
and size of main pancreatic duct on CT. Because IPMN is felt to
represent a disease progression along the adenoma–carcinoma
continuum,HGD was included with the invasive cancer group for
analysis as both HGD and invasive cancer are indications for
resection. Associations between variables were assessed using chi-
squared and Fisher’s exact tests as appropriate. Further analysis
was conducted with a multivariate logistic regression model in an
attempt to isolate characteristics that were independently predic-
tive of HGD or invasive cancer.We also looked at gender, age, duct
size1.0 cm and the maximum diameter of the lesions using CT
and EUS measurements. Computed tomography scans were per-
formed using a high-resolution, multi-detector 16- or 64-row
scanner.
Results
Fifty-two patients were identified, slightly more of whom (54%, n
= 28) were female. Their average age was 65 years. Final pathology
revealed that six (12%) patients had HGD and 11 (21%) had
invasive cancer. A total of 25% (13/52) had pancreatic duct dila-
tion of 1.0 cm as measured on the CT scan.
Endoscopic ultrasound with fine needle aspiration (FNA) was
performed in all but two patients, allowing for the comparison of
cytological findings. In lesions identified in final pathology as
IPMNs, the FNA detected mucin in only 32 (64%). Among the 17
patients with HGD or invasive cancer, cytology was read as ‘nega-
tive’ in five, as ‘positive’ in another five, and ‘atypical’ in seven. One
‘positive’ result referred to a patient who was found not to have
HGD or invasive cancer on final pathology, and 12 of 19 patients
with ‘atypical’ cells did not have HGD or invasive cancer. Levels of
CEA were measured in the cyst fluid in 26 patients. Ten of the 26
had a CEA value >200, but only two of these patients had HGD or
invasive cancer. Table 1 shows positive and negative predictive
values of EUS FNA for HGD or invasive cancer.
The diameters of the lesion and duct were also evaluated.
Numerical measurements of the lesion were obtained by both
EUS and CT in 47 of the 52 patients. The maximum diameter of
the lesion measured larger on EUS than on CT in 34 of the 47
patients. The accuracy of measurement criteria was compared
with the chi-squared test for diameters of both 2.5 cm and 3.0 cm.
Applying a CT scan diameter of 2.5 cm identified 12 of 17
patients with HGD or invasive cancer (P = 0.037), compared with
nine of 17 when using a CT scan diameter of3.0 cm (P = 0.118).
Applying an EUS diameter of 2.5 cm identified 12 of the 17
cases (P = 0.346), and using an EUS diameter of 3.0 cm identi-
fied 10 (P = 0.032). In a multivariate model, the maximum diam-
eter as a continuous variable on CT approached significance as a
predictor of HGD or invasive cancer (P = 0.056) (Table 2). The
addition of the diameter in EUS did not help in predicting HGD
or invasive cancer. Next we evaluated the duct size by CT scan.
Thirteen ducts were found to be1.0 cm in diameter and eight of
these 13 came from patients with HGD or invasive cancer. On
multivariate analysis, duct size1.0 cm was found to be an inde-
pendent predictor of HGD or invasive cancer (P = 0.034)
(Table 3). The positive and negative predictive values of duct size
1.0 cm, as well as lesion size2.5 cm, were calculated individu-
ally. We then combined the two CT measurement criteria and
calculated predictive values using the criteria of duct size1.0 cm
or lesion size 2.5 cm and found the negative predictive value to
Table 1 Endoscopic ultrasound with fine needle aspiration: positive
(PPV) and negative (NPV) predictive values for malignancy
PPV NPV
Positive cytology 83% 72%
Negative cytology 21% 52%
Mucin 30% 58%
CEA > 200 20% 75%
Table 2 Multivariate logistic regression model with diameter as a
continuous variable
Variable OR 95% CI P-value
CT lesion diameter (continuous) 1.44 0.99–2.094 0.056
Female gender 0.28 0.072–1.107 0.070
Age 0.99 0.923–1.073 0.892
OR, odds ratio; 95% CI, 95% confidence interval; CT, computed
tomography
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be 100% (Table 4). Of the 52 patients in our cohort, 17 had HGD
or invasive cancer, and all 17 would have been resected using CT
guidelines of lesion diameter 2.5 cm or duct size 1.0 cm.
Discussion
There remains great uncertainty about the accurate identification
of malignancy arising in IPMN. The purpose of this study was to
evaluate the two primary preoperative imaging techniques used at
this institution and their ability to predict HGD or invasive cancer.
In patients with pathology-proven IPMN, measurements
obtained with CT were smaller than those obtained with EUS, and
FNA cytological information was not helpful when differentiating
malignant from benign lesions. The use of CT criteria of lesion
size 2.5 cm or duct size 1.0 cm would have resulted in the
resection of all cases of IPMN with HGD or invasive cancer.
When to operate in IPMN has been the topic of a multitude of
papers.19–27 Most agree that main duct lesions should be removed,
but there are varying criteria for what differentiates main from
branch duct lesions. The international consensus guidelines state
that dilation of the main duct 1.0 cm strongly suggests main
duct IPMN.17 Bassi et al. asserts that main duct IPMN is charac-
terized by involvement of the duct of Wirsung, dilated to >1.0 cm
in diameter.28 Several other studies impose a cut-off at 5 mm or
6 mm.22,29,30 To determine when to resect the branch duct type,
they include other characteristics such as lesion size, with the
cut-off in the range of 3.0–4.0 cm,17,22,25,31,32 presence of mural
nodules,9,17 and protrusion of the nodule.3,33 Although the criteria
and risk for future malignancy in main and branch duct IPMN
differ, the focus of the present study was to evaluate duct and
lesion characteristics of IPMN as a whole that might predict the
presence of HGD or invasive cancer at the time of patient encoun-
ter with non-invasive imaging. Simplifying the criteria might help
clinicians to decide whether or not to resect and help them to
counsel patients on the risk that cancer or HGD is present in their
IPMN.
The primary imaging modality for the initial detection of pan-
creatic lesions is CT scan.11 Whether this is the most appropriate
diagnostic modality is a current topic of debate.3,11,16,34 Fisher et al.
looked at the accuracy of CT for predicting malignancy of all
cystic pancreatic lesions and found CT alone to be 61% accurate.34
However, only 11 of 48 patients had IPMN. Another study by
Cellier et al. looked at only IPMN patients and found CT to have
an accuracy of 76% to distinguish malignant features.16 This study
used conventional CT technology, not the high-resolution, multi-
detector CT scanners used in the present study. The introduction
of multi-detector CT technology has led to considerable improve-
ment in CT imaging quality. Higher-resolution CT can better
detect smaller lesions and associated masses, and delineate main
from branch duct IPMN.35 The results from the present study’s
cohort show that using the appropriate criteria, including duct
diameter 1.0 cm and/or mass 2.5 cm, achieves a sensitivity
and negative predictive value of 100%. Thus, in the population
studied, no lesions with HGD or invasive cancer would have been
missed. Some argue that EUS is a better test for malignant IPMN.
Mural nodules, a criteria for resection according to the interna-
tional guidelines,17 is one tumour characteristic best seen by EUS.
This was studied by Ohno et al., who found that the presence of
papillary or invasive mural nodules had an accuracy of 75%.9
However, because of the operator-dependent nature of EUS,
mural nodules may or may not be detected or reported. In the
present study, only one report found a mural nodule. The overall
accuracy of EUS has been quoted at 63%13 and at 86% with the
addition of FNA.10
The utility of FNA analysis has also been questioned. It adds
another element of invasive testing to the already invasive EUS.
Complications, including injury to adjacent organs, haemorrhage,
and the seeding of malignant cells into the peritoneum have been
reported.11 It also requires deep sedation, increases cost, is
operator-dependent and is not widely available. Maker et al.
report that over 60% of FNA cytology is non-diagnostic, carrying
a false negative rate of 72%.14 Another study found the accuracy to
be 56.5%.32 The data in the present study show that only 29% of
patients with malignancy had positive cytology. Although the
number of patients with measured fluid CEA was smaller, there
was no correlation between CEA values >200 and malignancy, as
has been suggested in the past.12 This is in agreement with Pais
et al., who found no difference in cyst fluid CEA between benign
and malignant IPMN.10
Lesion diameter has been shown to correlate with increased risk
for malignancy.17,22,25,31,32 Many of these measurements were deter-
mined using EUS. There are few data on how well CT and EUS
measurements correlate. In the present study, CT consistently
measured smaller than EUS (72%). This is very important when
considering pancreatic lesions.Most guidelines use measurements
of >3.0 cm as one of the criteria for increased malignant potential
Table 3 Multivariate logistic regression model with a dichotomized
diameter of 2.5 cm
Variable OR 95% CI P-value
CT duct  1.0 cm 27.2 1.28–580 0.034
CT lesion  2.5 cm 3.00 0.32–28.3 0.338
Age 0.92 0.80–1.07 0.279
Female gender 2.72 0.21–34.8 0.442
OR, odds ratio; 95% CI, 95% confidence interval; CT, computed
tomography
Table 4 Positive and negative predictive values for malignancy using
duct size, lesion size and the combination
CT criteria PPV NPV
Duct  1.0 cm 62% 90%
Lesion  2.5 cm 48% 80%
Duct  1.0 cm or lesion  2.5 cm 52% 100%
CT, computed tomography; PPV, positive predictive value; NPV, negative
predictive value; CT, computed tomography
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but do not specify by which imaging modality the measurement
should be obtained. Values of both 2.5 cm and 3.0 cm were tested
for differentiating HGD or invasive cancer from benign IPMN
and results showed that using a cut-off of 3.0 cm according to CT
scan would have caused several malignant lesions to be missed.
Applying this cut-off in combination with the resection criterion
of a duct diameter of 1.0 cm would still have allowed two
cancers to be undiagnosed.
This study has various limitations, including its retrospective
design. It only examined those patients with IPMN who were
surgically resected. Patients whomay have been observed, gone on
to develop cancer and undergone resection at another institution
would not have been included in this database. There may also
have been other variables predictive of HGD or invasive cancer
that were not identified by this study. This study does not include
patients with cystic neoplasms that proved to have different
pathologic diagnoses. Neither does it include patients with cystic
lesions suspicious for IPMN who did not undergo resection. The
patient sample is gathered from a single university hospital, which
is often, but not always, the referral site for uncommon lesions
such as IPMN. The data depend on the accuracy of the medical
record and the study lacks a control group.
In conclusion, IPMN is an uncommon but well-known lesion
of the pancreas that has the potential to harbour malignancy.
Diagnostic assessment has historically included cross-sectional
imaging and endoscopic evaluation. In this study’s cohort of
patients, EUS with or without FNA was unnecessary. Using mea-
surements of lesion size2.5 cm and/or pancreatic duct diameter
1.0 cm, obtained in CT imaging, would have led to the resection
of all tumours with HGD or cancer. This finding has substantial
applications for clinical practice, especially for settings in which
high-resolution CT is available but an experienced endosonogra-
pher is not.
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